Event Gaps: Perplexity's picks for 2026-10-09
Perplexity picked HUM, TEVA, DAL, AAPL, LITE for a 1-day horizon. Intraday alpha vs SPY: -2.50%. Picks with positive alpha: 0%.
| Experiment | Event Gaps |
|---|---|
| Model | Perplexity |
| Prompt version | event-gap-v12 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-10-09 |
| Measured to | 2026-10-12 |
| Benchmark | SPY |
| Status | Settled |
| Intraday alpha vs SPY | -2.50% |
| Picks with positive alpha | 0% |
| Benchmark return | +0.22% |
The picks
| Rank | Symbol | Gap direction | Price change | Return in the called direction | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|---|---|
| 1 | HUM | -0.40% | -0.40% | 72% | -0.62% | No | |
| 2 | TEVA | -1.22% | -1.22% | 63% | -1.44% | No | |
| 3 | DAL | +0.09% | -0.09% | 61% | -0.31% | No | |
| 4 | AAPL | +2.84% | -2.84% | 58% | -3.06% | No | |
| 5 | LITE | -6.85% | -6.85% | 55% | -7.07% | No |
The model's market view
US equities are stabilizing after a tech-led selloff, but single-stock catalysts remain dominant: Medicare star ratings, an FDA approval, airline earnings guidance, iPhone supply-chain reports, and AI optical-demand commentary can drive outsized one-day moves. I favor names with fresh, verifiable catalysts and sufficient liquidity, while acknowledging that large premarket gaps can mean emotional continuation or reversal during the session.
Why each pick
HUM
Humana is the strongest observed catalyst: CMS's 2027 Medicare Advantage Star Ratings were released and Humana said 95% of members would be in plans rated four stars or higher in 2027, versus 20% in 2026. This has occurred, and the stock surged roughly 15% premarket; quality ratings materially affect future Medicare bonus revenue. I expect continued upward follow-through as investors reprice 2027 revenue quality, though a 15% gap creates reversal risk if traders take profits or the broader managed-care complex fades. Reference price is a delayed premarket quote.
TEVA
Teva announced FDA approval of WELTRUZA (olanzapine) extended-release injectable suspension, its once-monthly subcutaneous long-acting injectable for schizophrenia in adults. The approval has occurred and TEVA rose about 4.2% premarket. A new branded LAI adds a potential growth and margin lever for a company still working through debt and generic-drug pressures, supporting continuation. Risks include profit-taking after the gap, launch-timing and reimbursement uncertainty, and the fact that the approval is already public rather than a future surprise. Reference price is a delayed premarket quote.
DAL
Delta reported Q3 adjusted EPS of $1.72 and revenue of $17.59 billion, below LSEG consensus of $1.75 and $17.67 billion, and cut its full-year earnings outlook while citing higher fuel costs. The earnings event has occurred. The stock fell about 4% premarket, and I expect additional downside as investors digest lower guidance, fuel-cost pressure, and the earnings call scheduled for 10:00 AM ET. The main risk is a rebound if management's commentary is more constructive than the headline guidance cut. Reference price reflects the latest available intraday/premarket data.
AAPL
Apple fell about 2.5% premarket after Nikkei Asia reported that Apple told some suppliers to cut component orders for iPhone 18 Pro and iPhone 18 Pro Max, with reports citing at least a 15% October order reduction. This is a news-driven, not company-confirmed, catalyst, so it is an uncertain expectation about demand rather than an officially scheduled event. Continued selling is plausible as investors mark down near-term iPhone unit assumptions, but Morgan Stanley reportedly did not detect major supply-chain changes and maintained estimates, creating a meaningful rebound risk. Reference price is a delayed premarket quote.
LITE
Lumentum rose 3.8% to 6% premarket after CEO Michael Hurlston said its optical components are effectively sold out through early 2029 and that the company may struggle to meet as much as 70% of demand for some products next year. This is an observed management commentary catalyst, not a scheduled earnings release. The commentary supports an upward repricing of optical/AI infrastructure demand, but the stock is extremely expensive and volatile, and a large premarket move can reverse if the broader AI trade weakens. Reference price is the latest available premarket indication; an exact live regular-session price was not available in the evidence gathered.
Other models on the same run
| Model | Picks | Intraday alpha vs SPY | Picks with positive alpha |
|---|---|---|---|
| GPT-6 | HUM, CCI, TMUS, T, DAL | +0.16% | 20% |
| Muse Spark 1.1 | DAL, TMUS, T, VZ, LEVI | -0.40% | 40% |
| Gemini 1.5 Pro | DAL, AAPL, HUM, CEG, AMD | +0.17% | 40% |
| Grok 4.5 | DAL, VZ, TMUS, JPM, GS | +0.47% | 60% |
| Claude Sonnet 5.5 | HUM, TMUS, LITE, CCI, DAL | -2.52% | 0% |
| DeepSeek | HUM, TEVA, T, VZ, AAPL | -0.88% | 20% |
Written up on ForecastNest Insights: Event Gaps: Perplexity's picks for 2026-10-09.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.